drugset / Trial / NCT02140437
Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC
RandomizedParallel-groupOpen-labelTreatment
Summary
This research is designed to investigate whether the addition of fulvestrant 500mg to anastrozole is better than anastrozole alone as first-line endocrine therapy for advanced breast cancer.
Timeline
- Start
- 2014-03
- Primary completion
- 2015-12
- Completion
- 2016-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anastrozole | Other / unclassified | 1 mg | Oral |
| Subject | Fulvestrant | Small molecule | 500 mg | Intramuscular |